The obesity epidemic persists as a formidable healthcare challenge, catalyzing strategic investment in novel pharmaceutical approaches. Current pipeline analysis reveals multiple obesity drugs in development with differentiated mechanisms and competitive positioning potential. Retatrutide has captured significant market attention as a potentially disruptive therapeutic asset. Strategic...